drug
-
Global generic drug markets will grow to US$221 billion by 2016
Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favored.
drug | 23 May 2012
-
US Supreme Court clears way for generic patent challenges
After the ruling, generic manufacturers will now be able to challenge the content of patent descriptions and, if successful, ultimately force approval of the ANDA. Writing for the Court in a unanimous decision, Justice Elena Kagan chastised the FDA for using ambiguous or opaque guidelines and forms that lend to the confusion surrounding patent decisions.
drug | 18 May 2012
-
More investment needed in anti-obesity drugs
Pharmaceutical companies should increase their investment in anti-obesity drug therapies to support the growing number of clinically obese individuals worldwide, a report by GlobalData has found.
drug | 01 May 2012
-
Technology gains renewing interest in needle arrays as drug delivery devices
Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered.
drug | 12 April 2012
-
Refinements in inhaled drug delivery enhances growth prospects as global markets emerge
Survey finds evolving device technologies creating opportunities for drug developers, according to Greystone Research Associates.
drug | 10 April 2012
-
Emphasis on reconstituting drugs at the point-of-care driven by growth in lyophilized drugs
The push to intuitive technology is seen as reducing medication errors according to Greystone Research Associates.
drug | 14 March 2012
-
Weak narcolepsy drug pipeline provides opportunities for pharma companies
The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing opportunities for drugs companies to expand into this market, a study by healthcare intelligence specialist GlobalData has found.
drug | 07 March 2012
-
US FDA clears investigational new drug application, phase 2B trial for Immuron’s NASH/Fatty liver therapeutic
Immuron announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission to commence a Phase 2b clinical trial of its bovine colostrum-derived therapeutic (IMM-124E) for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver.
drug | 06 March 2012
-
Generic drug manufacturers forge alliances in face of tough economic climate
The generic drugs sector’s role as the provider of affordable drugs has widely benefitted public and private health payers keen to control costs. But in the current economic climate, downward pressure on prices is impacting the generic sector, with increases in acquisition and strategic partnering now firmly part of the competitive landscape.
drug | 28 February 2012
-
Modern drug testing
TÜV SÜD PSB is equipped with modern analytical testing equipments to help companies meet the necessary product quality and validation requirements for drugs and pharmaceutical products. Pharma Asia visited the facility in Singapore to fi nd out more.
drug | 27 January 2012
